Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Octreotide acetate
Drug ID BADD_D01595
Description Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction.[L14501] In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may also occur. Acromegaly is a life-threatening disease requiring life-long management.[L14501] Octreotide is a long-acting drug with pharmacologic activities that mimic those of the natural hormone, somatostatin, which inhibits the secretion of growth hormone.[L14513] Additionally, it is used for the treatment of acromegaly and symptoms arising from various tumors, including carcinoid tumors and vasoactive intestinal tumors (VIPomas).[L14513] In the past, octreotide has been administered solely by injection. On June 26, 2020, the first approved delayed-release oral somatostatin analog, Mycapssa, received FDA approval for the long term maintenance treatment of acromegaly. This drug was developed by Chiasma Inc.[L14495,L14507,L14528]
Indications and Usage For treatment of acromegaly and reduction of side effects from cancer chemotherapy
Marketing Status Prescription; Discontinued
ATC Code H01CB02
DrugBank ID DB00104
KEGG ID D02250
MeSH ID D015282
PubChem ID 6917964
TTD Drug ID D02XIY
NDC Product Code 59651-004; 0078-0180; 76177-119; 67457-245; 65015-840; 55463-0035; 25021-451; 0703-3333; 0703-3301; 63415-0065; 67457-246; 0078-0182; 0703-3311; 0641-6174; 0078-0818; 66558-0192; 63323-378; 0641-6177; 63323-376; 0703-3321; 63323-379; 63629-8831; 0641-6176; 0641-6175; 66558-0180; 65129-1049; 25021-452; 0078-0811; 63557-0019; 25021-454; 63323-377; 25021-455; 67457-239; 0703-3343; 0641-6178; 25021-453; 52416-123; 0078-0825; 32861-0005; 0078-0181
Synonyms Octreotide | SMS 201-995 | SMS 201 995 | SMS 201995 | SM 201-995 | SM 201 995 | SM 201995 | Sandoz 201-995 | Sandoz 201 995 | Sandoz 201995 | Compound 201-995 | Compound 201 995 | Compound 201995 | SAN 201-995 | SAN 201 995 | SAN 201995 | Octreotide Acetate | Octreotide Acetate Salt | Sandostatine | Sandostatin
Chemical Information
Molecular Formula C51H70N10O12S2
CAS Registry Number 79517-01-4
SMILES CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4= CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O.CC(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Blood alkaline phosphatase increased13.04.02.004--
Urine output increased13.13.03.002--Not Available
Hepatic enzyme increased13.03.01.019--Not Available
Hot flush08.01.03.027; 24.03.01.005; 21.02.02.001--
Cardiac disorder02.01.01.003--Not Available
Ischaemia24.04.02.004--Not Available
Malnutrition14.03.02.004--Not Available
Mental disorder19.07.01.002--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Ill-defined disorder08.01.03.049--Not Available
Psychotic disorder19.03.01.002--
Hepatobiliary disease09.01.08.003--Not Available
Lung neoplasm22.08.01.006; 16.19.04.001--Not Available
Cystitis noninfective20.03.02.001--
Anorectal discomfort07.03.03.003--Not Available
Oropharyngeal discomfort07.05.05.008; 22.02.05.027--Not Available
Oropharyngeal pain22.02.05.022; 07.05.05.004--
Candida infection11.03.03.021--
The 9th Page    First    Pre   9    Total 9 Pages